SCHEMBL16408949

SCHEMBL16408949

CC1CN(C(=O)Cc2ccccc2)CCc2ccc(Cl)cc21

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ DRD3 P35462 8/20 0.48
▸ DRD2 P14416 8/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ POLB P06746 1/20 0.48
▸ FNTA P49354 2/20 0.47
▸ FNTB P49356 2/20 0.47
▸ HTR1A P08908 5/20 0.47
▸ HTR2A P28223 2/20 0.47
▸ HRH1 P35367 1/20 0.47
▸ ATM Q13315 2/20 0.46
▸ SLC6A15 Q9H2J7 1/20 0.46
▸ TACR3 P29371 1/20 0.45
▸ HHAT Q5VTY9 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ GPR183 P32249 1/20 0.45
▸ GFER P55789 1/20 0.44
▸ KCNH2 Q12809 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16408979 1.00 DRD3 (0.48) DRD3DRD2KMT2ANPC1ALDH1A1
SCHEMBL3782375 0.80 NOTUM (0.50) DRD3DRD2HTR1AHTR2AHRH1
SCHEMBL16408968 0.80 NOTUM (0.50) DRD3DRD2HTR1AHTR2AHRH1
SCHEMBL3782373 0.80 NOTUM (0.50) DRD3DRD2HTR1AHTR2AHRH1
SCHEMBL16408948 0.80 NOTUM (0.50) DRD3DRD2HTR1AHTR2AHRH1
SCHEMBL3780250 0.80 KDM4E (0.47) DRD3DRD2ALDH1A1HTR1AHTR2A
SCHEMBL3780247 0.80 KDM4E (0.47) DRD3DRD2ALDH1A1HTR1AHTR2A
SCHEMBL3282297 0.76 ESR1 (0.49) DRD3DRD2HTR1AHTR2AHRH1
SCHEMBL3282323 0.76 ESR1 (0.49) DRD3DRD2HTR1AHTR2AHRH1
SCHEMBL31121204 0.76 ESR1 (0.49) DRD3DRD2HTR1AHTR2AHRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015007897-A1 METHOD OF RACEMISATION OF UNDESIRED ENANTIOMERS LEK PHARMACEUTICALS D.D. (SI) 2015-01-22 — — WO disclosed
Send feedback